{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:47:41Z","timestamp":1792320461927,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40265-021-01576-0","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T16:02:43Z","timestamp":1628352163000},"page":"1587-1591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Contezolid: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"issue":"2","key":"1576_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/microorganisms8020191","volume":"8","author":"D Koulenti","year":"2020","unstructured":"Koulenti D, Xu E, Song A, et al. Emerging treatment options for infections by multidrug-resistant Gram-positive microorganisms. Microorganisms. 2020;8(2):191.","journal-title":"Microorganisms"},{"key":"1576_CR2","unstructured":"MicuRx Pharmaceuticals. China NMPA approves MicuRx\u2019s contezolid for treatment of drug-resistant bacterial infection [media release]. 2 Jun 2021. http:\/\/www.micurx.com\/."},{"key":"1576_CR3","unstructured":"National Medical Products Administration. The State Food and Drug Administration approves the listing of contezolid tablets. 2021. http:\/\/www.nmpa.gov.cn\/yaowen\/ypjgyw\/20210602083301144.html?type=pc&m=. Accessed 8 Jun 2021."},{"key":"1576_CR4","unstructured":"Shanghai MicuRx Pharmaceutical Co. Ltd. Youxitai \u4f18\u559c\u6cf0\u00ae (contezolid \u5eb7\u66ff\u5511\u80fa tablets): Chinese prescribing information. Shanghai: Shanghai MicuRx Pharmaceutical Co., Ltd.; 2021."},{"key":"1576_CR5","unstructured":"MicuRx Pharmaceuticals. MicuRx reports positive top-line results of a China phase 3 clinical trial for novel antibiotic contezolid in complicated skin and soft tissue infections [media release]. 20 Sep 2019. http:\/\/www.micurx.com."},{"issue":"5","key":"1576_CR6","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1021\/acs.chemrestox.0c00524","volume":"34","author":"W Wang","year":"2021","unstructured":"Wang W, Voss KM, Liu J, et al. Nonclinical evaluation of antibacterial oxazolidinones contezolid and contezolid acefosamil with low serotonergic neurotoxicity. Chem Res Toxicol. 2021;34(5):1348\u201354.","journal-title":"Chem Res Toxicol"},{"key":"1576_CR7","unstructured":"MicuRx Pharmaceuticals. MicuRx reports positive top-line results from phase 2 US clinical trial for novel antibiotic MRX-I [media release]. 3 Nov 2015. http:\/\/www.micurx.com."},{"issue":"11","key":"1576_CR8","doi-asserted-by":"publisher","first-page":"e01195-20","DOI":"10.1128\/AAC.01195-20","volume":"64","author":"CG Carvalhaes","year":"2020","unstructured":"Carvalhaes CG, Duncan LR, Wang W, et al. In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against Gram-positive clinical isolates from the United States and Europe. Antimicrob Agents Chemother. 2020;64(11):e01195-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1576_CR9","doi-asserted-by":"publisher","first-page":"e00493-18","DOI":"10.1128\/AAC.00493-18","volume":"62","author":"C Shoen","year":"2018","unstructured":"Shoen C, DeStefano M, Hafkin B, et al. In vitro and in vivo activities of contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018;62(8):e00493-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1576_CR10","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1128\/AAC.01526-13","volume":"58","author":"CR Li","year":"2014","unstructured":"Li CR, Zhai QQ, Wang XK, et al. In vivo antibacterial activity of MRX-I, a new oxazolidinone. Antimicrob Agents Chemother. 2014;58(4):2418\u201321.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1576_CR11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.clinthera.2020.03.020","volume":"42","author":"L Li","year":"2020","unstructured":"Li L, Wu H, Chen Y, et al. Population pharmacokinetics study of contezolid (MRX-I), a novel oxazolidinone antibacterial agent, in Chinese patients. Clin Ther. 2020;42(5):818\u201329.","journal-title":"Clin Ther"},{"issue":"2","key":"1576_CR12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clinthera.2017.12.017","volume":"40","author":"X Wu","year":"2018","unstructured":"Wu X, Li Y, Zhang J, et al. Short-term safety, tolerability, and pharmacokinetics of MRX-I, an oxazolidinone antibacterial agent, in healthy Chinese subjects. Clin Ther. 2018;40(2):322-32.e5.","journal-title":"Clin Ther"},{"issue":"5","key":"1576_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1124\/dmd.114.061747","volume":"43","author":"J Meng","year":"2015","unstructured":"Meng J, Zhong D, Li L, et al. Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metab Dispos. 2015;43(5):646\u201359.","journal-title":"Drug Metab Dispos"},{"key":"1576_CR14","unstructured":"MicuRx Pharmaceuticals. MicuRX reports positive top-line results in phase 2 clinical trial for novel antibiotic MRX-I in complicated skin and soft tissue infections [media release]. 31 Aug 2015. http:\/\/www.micurx.com."},{"key":"1576_CR15","unstructured":"US National Institutes of Health. MRX-I versus linezolid for the treatment of acute bacterial skin and skin structure infection (ABSSSI). 2017. http:\/\/clinicaltrials.gov\/. Accessed 18 Jun 2021."},{"key":"1576_CR16","unstructured":"MicuRx Pharmaceuticals. MicuRx closes $55 million Series C Financing to support development of next-generation antibiotic MRX-I [media release]. 27 Sep 2016. http:\/\/www.micurx.com."}],"updated-by":[{"DOI":"10.1007\/s40265-021-01627-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01576-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01576-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01576-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T10:50:44Z","timestamp":1634986244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01576-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":16,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1576"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01576-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,7]]},"assertion":[{"value":"7 August 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Digital Features update","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01627-6","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01627-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}